Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- PMID: 32333918
- PMCID: PMC7177073
- DOI: 10.1016/j.jinf.2020.04.017
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Abstract
Comment in
-
Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.05.020. Epub 2020 May 15. J Infect. 2020. PMID: 32422152 Free PMC article. No abstract available.
-
[Baricitinib in the treatment of SARS-CoV-2 infection].Rev Esp Quimioter. 2020 Aug;33(4):294-295. doi: 10.37201/req/047.2020. Epub 2020 Jun 25. Rev Esp Quimioter. 2020. PMID: 32583654 Free PMC article. Spanish. No abstract available.
-
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.J Infect. 2020 Oct;81(4):647-679. doi: 10.1016/j.jinf.2020.06.052. Epub 2020 Jun 24. J Infect. 2020. PMID: 32592703 Free PMC article.
Comment on
-
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Lancet. 2020. PMID: 31986264 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources